以色列2023年丙型肝炎消除国家规划的经济学分析
2021年以色列卫生部启动丙型肝炎消除国家规划,采用靶向筛查、简化流程和患者登记等措施。截至2023年5月15日,在865,382名高危人群中筛查555,083人(64.3%),检出HCV 24,361人(4.4%),其中13,379人检出病毒血症,10,711人接受治疗,4,618人获得持续病毒学应答。每例确诊并成功治疗者的费用估计为14,426新谢克尔(约3,606美元)。
要点
- 高危人群中64.3%接受了血清学筛查,HCV检出率4.4%。
- 病毒血症者中80%接受治疗,96.5%获得持续病毒学应答。
- 每例确诊并成功治疗者的费用为14,426新谢克尔(约3,606美元)。
核心结论
- 该规划在近三分之二识别出的高危人群中完成了筛查和治疗,丙型肝炎虽未消除,但患病率到2030年目标时可能大幅下降。
研究设计与样本
- 评估以色列2021年启动的丙型肝炎消除国家规划中检测和治疗费用的经济学分析。
主要发现
- 截至2023年5月15日,规划识别865,382名高危者,其中555,083人(64.3%)接受HCV血清学筛查,24,361人(4.4%)检出HCV。
- 20,928例血清学阳性患者中,13,379人(63.9%)检出病毒血症。
- 13,379例病毒血症者中10,711人(80%)接受治疗;4,786名治疗后接受HCV RNA检测者中4,618人(96.5%)获得持续病毒学应答。
- 每例HCV感染确诊并成功治疗者的费用估计为14,426新谢克尔(约3,606美元)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In 2021, the Israel Ministry of Health began a national hepatitis C elimination program. Implementing a World Health Organization goal, Israel's program involved targeted screening, barrier minimization, workup simplification, awareness campaigns, and a patient registry. We evaluated program costs for testing and treatment. By May 15, 2023, the program had identified 865,382 at-risk persons, of whom 555,083 (64.3%) were serologically screened for hepatitis C virus (HCV), which was detected in 24,361 (4.4%). Among 20,928 serologically positive patients, viremia was detected in 13,379 (63.9%), of whom 10,711 (80%) were treated, and 4,618 (96.5%) of 4,786 persons receiving posttreatment HCV RNA testing had sustained virologic response. We estimated costs of ₪14,426 (new Israel shekel; ≈$3,606 USD) per person whose HCV infection was diagnosed and successfully treated. The program yielded screening and treatment in almost two thirds of the identified at-risk population. Although not eliminated, HCV prevalence will likely decrease substantially by the 2030 target.
引用
- Dadon Y, Mimouni FB, Toren A, et al. Economic Analysis of National Program for Hepatitis C Elimination, Israel, 20231. Emerg Infect Dis. 2024. PMID: 39320161. doi:10.3201/eid3010.240210
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。